US Q4 Consumer Health Earnings Preview: Inflation Impact Follows Pandemic-Driven Disruption
Executive Summary
Cost increases initially spurred by supply chain disruptions by COVID-19 pandemic have been noted by businesses across consumer product industries since soon after novel coronavirus spread accelerated in early 2020. More recently, OTC drug, nutritional supplement and personal care product providers began noting inflation’s influence on costs.
You may also be interested in...
J&J Full Steam Ahead On Separating Consumer Business While Inflation, Pandemic Slow Results
While target date for spinning out consumer business into publicly traded company remains some time in 2023, J&J includes additional details on separation timetable with its 2021 full-year and fourth-quarter results.
P&G Widens Pricing Strategy To At Least 60% Of Products As Costs Soar
Procter & Gamble’s pricing strategy now impacts 10 of its US product categories, with action also being taken broadly in non-US markets. President and CEO Jon Moeller calls this pricing "at a different level" historically speaking, and warns there will be ‘bumps in the road." But P&G is confident in its long track record and raises full-year guidance accordingly.
Perrigo Steers Through Transportation Obstacles, Soaring Shipping Costs From COVID-19
Perrigo largely has resolved distribution problems, but shipping freight costs still are much higher than pre-pandemic and it must divest a wound-care brand before US regulators sign off on acquisition of HRA Pharma, says CEO Murray Kessler during J.P. Morgan conference.